ReviewPharmaceutical research2018
Glaucoma - Next Generation Therapeutics: Impossible to Possible.
Review in Pharmaceutical research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Research on neurotrophic factor for glaucoma: a worldwide bibliometric analysis.International journal of ophthalmology · 2025Article
- Single-cell transcriptomic Atlas of aging macaque ocular outflow tissues.Protein & cell · 2024Article
- Epigenetics in Glaucoma.Medicina (Kaunas, Lithuania) · 2024Review
- AAV-mediated gene therapies for glaucoma and uveitis: are we there yet?Expert reviews in molecular medicine · 2024Review
- Article
- Sustained release of brimonidine from BRI@SR@TPU implant for treatment of glaucoma.Drug delivery · 2022Article
- Optic Nerve Head Myelin-Related Protein, GFAP, and Iba1 Alterations in Non-Human Primates With Early to Moderate Experimental Glaucoma.Investigative ophthalmology & visual science · 2022Article
- Atorvastatin reduces IOP in ocular hypertensionInternational journal of molecular medicine · 2022Article
- The role of miRNA in retinal ganglion cell health and disease.Neural regeneration research · 2022Review
- 1α,25-dihydroxyvitamin DJournal of neuroinflammation · 2021Article
- S100-β aggravates spinal cord injury via activation of M1 macrophage phenotype.Journal of musculoskeletal & neuronal interactions · 2021Article
- Rebaudioside A/TPGS mixed nanomicelles as promising nanocarriers for nimodipine ocular delivery.Drug delivery and translational research · 2021Article
- Involvement of c-Jun N-terminal kinase 2 (JNK2) in Endothelin-1 (ET-1) Mediated Neurodegeneration of Retinal Ganglion Cells.Investigative ophthalmology & visual science · 2021Article
- Quantification of Retinal Ganglion Cell Morphology in Human Glaucomatous Eyes.Investigative ophthalmology & visual science · 2021Article
- Retrospective Chart Review on Real-World Use of Latanoprostene Bunod 0.024% in Treatment-Naïve Patients with Open-Angle Glaucoma.Ophthalmology and therapy · 2020Article
- Molecular taxonomy of human ocular outflow tissues defined by single-cell transcriptomics.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Retinal Tissue Bioengineering, Materials and Methods for the Treatment of Glaucoma.Tissue engineering and regenerative medicine · 2020Review
- CRISPR-Cas9 Disruption of Aquaporin 1: An Alternative to Glaucoma Eye Drop Therapy?Molecular therapy : the journal of the American Society of Gene Therapy · 2020Article
- 17β-Estradiol Delivered in Eye Drops: Evidence of Impact on Protein Networks and Associated Biological Processes in the Rat Retina through Quantitative Proteomics.Pharmaceutics · 2020Article
- Adaptive Immunity: New Aspects of Pathogenesis Underlying Neurodegeneration in Glaucoma and Optic Neuropathy.Frontiers in immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The future of next generation therapeutics for glaucoma is strong. The recent approval of two novel intraocular pressure (IOP)-lowering drugs with distinct mechanisms of action is the first in over 20 years. However, these are still being administered as topical drops. Efforts are underway to increase patient compliance and greater therapeutic benefits with the development of sustained delivery technologies. Furthermore, innovations from biologics- and gene therapy-based therapeutics are being developed in the context of disease modification, which are expected to lead to more permanent therapies for patients. Neuroprotection, including the preservation of retinal ganglion cells (RGCs) and optic nerve is another area that is actively being explored for therapeutic options. With improvements in imaging technologies and determination of new surrogate clinical endpoints, the therapeutic potential for translation of neuroprotectants is coming close to clinical realization. This review summarizes the aforementioned topics and other related aspects.
Indexed as
Identifiers
30547244What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.